AI boosts cancer diagnosis speed in small study
NCT ID NCT07203885
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether artificial intelligence (AI) can help doctors diagnose a rare blood cancer called acute promyelocytic leukemia (APL) more quickly and accurately. Ten doctors reviewed bone marrow samples with and without AI assistance. The goal was to see if AI improves diagnostic accuracy, speed, and confidence.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKAEMIA (AML) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Harvard Medical School
Boston, Massachusetts, 02115, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New hope for AML patients: experimental drug IPN60340 enters key trial
- New drug aims to stop deadly complication in leukemia therapy
- New pill could transform leukemia treatment, phase 3 trial begins
- New blood test could personalize AML treatment
- Why do some Low-Risk leukemia patients relapse? scientists look to bone marrow cells for answers
- New drug cocktail aims to wipe out lingering leukemia